

4 November 2024 EMA/94136/2024 Committee for Medicinal Products for Human Use (CHMP)

Methylphenidate, prolonged-release tablet 18 mg, 27 mg, 36 mg and 54 mg and modified release capsule 5 mg, 10 mg, 20 mg, 30 mg, 40 mg, 50 mg and 60 mg product-specific bioequivalence guidance

Draft Agreed by Methodology Working Party (MWP)	23 April 2024
Adopted by CHMP for release for consultation	21 May 2024
Start of public consultation	25 June 2024
End of consultation (deadline for comments)	30 September 2024
Final Agreed by Methodology Working Party (MWP)	21 October 2024
Adopted by CHMP	04 November 2024
Start of public consultation	01 September 2025

Keywords

Bioequivalence, generics, methylphenidate

 Official address
 Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands

 Address for visits and deliveries
 Refer to www.ema.europa.eu/how-to-find-us

 Send us a question
 Go to www.ema.europa.eu/contact

 Telephone +31 (0)88 781 6000
 An agency of the European Union



C European Medicines Agency, 2025. Reproduction is authorised provided the source is acknowledged.



Methylphenidate, prolonged-release tablet 18 mg, 27 mg, 36 mg and 54 mg and modified release capsule 5 mg, 10 mg, 20 mg, 30 mg, 40 mg, 50 mg and 60 mg product-specific bioequivalence guidance

Disclaimer:

This guidance should not be understood as being legally enforceable and is without prejudice to the need to ensure that the data submitted in support of a marketing authorisation application complies with the appropriate scientific, regulatory and legal requirements.

Requirements for bioequivalence demonstration (MWP)

Bioequivalence study design	For Single Unit Formulations
	Single dose fasting: All strengths or bracketing approach, healthy volunteers.
	Single dose fed: The highest/most sensitive strength in healthy subjects may be sufficient provided that, in addition to the usual waiver of strength criteria, the shape of the formulations of the strengths should be similar.

 Official address
 Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands

 Address for visits and deliveries
 Refer to www.ema.europa.eu/how-to-find-us

 Send us a question
 Go to www.ema.europa.eu/contact

 Telephone +31 (0)88 781 6000
 An agency of the European Union



o European Medicines Agency, 2025. Reproduction is authorised provided the source is acknowledged.

	Background: Single dose fasting and fed studies are required for prolonged-release formulations without accumulation.	
	For Multiple Unit Formulations	
	Single dose fasting: Highest strength, healthy volunteers.	
	Single dose fed: Highest strength, healthy volunteers.	
	Background: Single dose fasting and fed studies are required for prolonged-release formulations without accumulation.	
	cross-over	
Analyte	🛛 parent 🗌 metabolite 🗌 both	
	🛛 plasma/serum 🗌 blood 🗌 urine	
	Enantioselective analytical method: 🗌 yes 🛛 no	
Bioequivalence assessment	Main pharmacokinetic variables:	
	Single dose fasting: AUC _{0-t} , AUC _{0-inf} , C _{max} , AUC _{0-3h} , C _{max0-3h} , AUC _{3-24h} and Cmax _{3-24h}	
	Single dose fed: AUC _{0-t} , AUC _{0-inf} , C _{max} , AUC _{0-4h} , C _{max0-4h} , AUC _{4-24h} and Cmax _{4-24h}	
	90% confidence interval: 80.00- 125.00%	
	To be noted: <i>In vitro</i> studies of release in alcohol solutions should also be performed. <i>In vitro</i> compatibility with mixing with applesauce should be demonstrated where applicable.	

Methylphenidate, prolonged-release tablet 18 mg, 27 mg, 36 mg and 54 mg and modified release capsule 5 mg, 10 mg, 20 mg, 30 mg, 40 mg, 50 mg and 60 mg product-specific bioequivalence guidance EMA/274853/2024